Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0042109 (urticaria)
 6,569 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Three patients with chronic urticaria, two of whom also had angioedema, were treated with oral cyclosporine, 6 mg/kg per day. In each patient, complete resolution of symptoms occurred within the first week of therapy; however, all patients eventually had to stop therapy as a result of side effects. On stopping therapy, all side effects resolved and the urticaria and angioedema recurred. Although cyclosporine therapy is not an appropriate treatment of urticaria, the results of this preliminary study suggest that cyclosporine and related drugs should be investigated in the treatment of mast cell-mediated diseases.
 ...
PMID:Oral cyclosporine for severe chronic idiopathic urticaria and angioedema. 143 Mar 81

Schnitzler's syndrome is characterized by chronic urticaria, recurrent fever, bone pain, and lymphadenopathy in conjunction with a serum IgM M component in a concentration that is usually less than 10,000 mg/L. Complement activation and cryoprecipitation do not appear to be involved. We report two additional patients who share many of the characteristics of this entity. These patients differ from patients previously reported because of the markedly elevated IgM M-component concentration in one patient and the severity of anemia in the second patient. An increased frequency of IgG autoantibodies to interleukin-1-alpha has been reported by other investigators; it has been suggested that an antibody-mediated prolongation of the half-life of interleukin-1-alpha might account for some of the symptoms and signs of this disorder. However, neither the mediators involved in the induction of nonpruritic urticaria nor the role of the IgM M component has been established.
 ...
PMID:Schnitzler's syndrome: a broader clinical spectrum. 182 7

The effects of oral cetirizine on spontaneous and provoked urticaria were evaluated in two studies. In a double-blind crossover trial, 30 patients with idiopathic urticaria received 10 or 20 mg of cetirizine or placebo. Cetirizine was significantly more effective than placebo in reducing the incidence of erythema, wheals, and pruritus. No serious side effects were reported. In the second study of ten patients with chronic urticaria, immediate and delayed reactions to injected autologous serum, histamine, kallikrein, and synthetic platelet-activating factor (PAF)-acether were inhibited by 10 mg of cetirizine. These results suggest that the mechanism of action of cetirizine may involve inhibition of PAF-induced influx of eosinophils.
 ...
PMID:Cetirizine in the treatment of chronic urticaria. 182 14

The levels of tryptase in the suction-blister fluid from patients with chronic urticaria, urticaria pigmentosa, cholinergic urticaria, urticarial dermographism, prurigo of unknown origin, eczema, psoriasis, atopic dermatitis, and from healthy controls were studied. The blister fluid from controls contained up to 15 micrograms/l of tryptase, whereas that from patients with active urticaria contained greater than 50 micrograms/l. This study demonstrates that patients with urticaria have mast cells that readily release tryptase in both the lesional and non-lesional areas of skin.
 ...
PMID:Increased tryptase levels in suction-blister fluid from patients with urticaria. 187 96

In a prospective analysis, all patients presenting with urticaria in the practices of a general practitioner and a dermatologist and at a university clinic in the course of a year were ascertained and underwent diagnostic examination according to a uniform scheme. Urticarias are common skin diseases, affecting, at a modest estimate, about 1.3% of the population. Of all the general practitioner's patients about 3% had one of the many types of urticaria. The same percentage was found in the dermatologist's practice and among the patients attending the university clinic. The incidence of the different types of urticaria differs considerably at the different levels of medical care. This may be due to the fact that the patients are referred to a specialist or to a clinic only when the diagnosis or treatment is problematic. Half the general practitioner's urticaria patients suffer from physical urticarias (this includes the minor variants that do not necessarily require medical care). In the clinic, however, only a quarter of all patients with urticaria had physical variants. Patients with chronic urticaria accumulate in clinics because they have been referred for diagnosis and therapy. Predominantly young people were affected by physical urticaria, the peak being between 10 and 40 years. Patients with chronic "endogenous" urticaria were significantly older. About 30% of all patients also had angio-oedema, at least temporarily. Isolated swelling without urticaria occurred in only 3.9% of all patients. In urticaria, there was a slight female predominance: of all patients with physical urticaria, 61.1% were female, and the corresponding figure for nonphysical types was 53.6%. An almost equal sex distribution was found in chronic urticaria (51.9% female). In our prospective study patients presenting with urticaria only as a minor symptom was also ascertained. Many minor variants of physical urticaria were seen in these patients. In the dermatological practice, urticaria was diagnosed incidentally in 6-8% of cases. In the clinic, however, 20% of the physical urticarias and 10% of the acute nonphysical urticarias were recorded as incidental findings.
 ...
PMID:[Epidemiology of urticaria diseases]. 191 59

The effects of oral administration of the antihistamine cetirizine on the weal and flare caused by intradermal injection of platelet activating factor (PAF-acether), kallikrein, histamine and the patient's own serum were investigated in 10 patients with chronic urticaria. Cetirizine markedly reduced the weal and flare induced by all these agents as measured 12 min after the injections. The delayed reactions observed after injection of PAF, kallikrein and serum were also inhibited by cetirizine at 6 hours. In addition, reactions which were present 20 h after injection of the agent before administration of cetirizine were found to be inhibited at the same point in time after cetirizine treatment. These effects might explain the good inhibitory clinical effect of cetirizine on the patients' urticaria. No side-effects were noted during the treatment.
 ...
PMID:Effect of cetirizine on cutaneous reactions to PAF, kallikrein and serum in patients with chronic urticaria. 196 2

Urticaria affects 15% to 20% of the population once or more during a lifetime. Chronic urticaria is a frequent recurrent eruption over a period greater than 6 weeks; the cause remains a mystery in more than 75% of cases. Urticaria and angioedema may be produced by immunologic or nonimmunologic means. Urticarial vasculitis, contact urticaria, mastocytosis, physical urticarias, dermatographism, cholinergic urticaria, localized heat urticaria, cold urticaria, aquagenic urticaria, and vibratory angioedema all require specific evaluation and treatment. Chronic idiopathic urticaria is usually controlled by antihistamines; depending on the circadian rhythm of the eruption, sedative or nonsedative antihistamines are prescribed. Some patients will require a combination of H1 and H2 antagonists, or even parenteral corticosteroids.
 ...
PMID:Chronic urticaria. 197 Jun 97

Oxatomide (Tinset) is a new, powerful, antiallergic agent. Pharmacological and morphological studies have shown that oxatomide is not only an antihistaminic agent but it also inhibits mast cells and basophils degranulation, and neoformed mediators synthesis and release. Open and comparative studies have shown oxatomide to be an effective agent in the treatment of chronic urticaria including physical urticaria and food allergy. All these studies confirm its constant efficacy, giving good to excellent results in 68 to 89 percent of cases. It compares favorably with the classic anti-H1, particularly in that the symptomatic response is much quicker. Moreover the drug is always well tolerated, even when used at higher doses than those presently recommended (30 mg twice daily).
 ...
PMID:[Chronic urticaria: role of oxatomide]. 197 25

Chronic urticaria is a problem for both physician and patient. In an effort to avoid the risks associated with corticosteroid treatment, many first-generation H1-receptor antagonists have been tried and found to induce undesirable levels of sedation when given in amounts sufficient to control urticaria. Cetirizine, a pharmacologically active oxidized metabolite of hydroxyzine, was developed to provide selective H1-receptor inhibition without depression of the central nervous system. In a 4-week, multicenter, double-blind, placebo-controlled safety and efficacy study, cetirizine, in a once-a-day dose (5 to 20 mg), was equivalent in efficacy to hydroxyzine in divided doses (25 to 75 mg/day). The incidence of somnolence in the cetirizine group was not significantly different from that of the placebo group. However, in the hydroxyzine group, the incidence of somnolence was significantly higher than that in the placebo group (p = 0.001). The results of this study demonstrate that cetirizine has a greater safety margin over the older parent drug hydroxyzine.
 ...
PMID:Urticaria: clinical efficacy of cetirizine in comparison with hydroxyzine and placebo. 197 96

To evaluate the possible association of malignant disease with chronic urticaria 1155 consecutive cases with chronic urticaria were reviewed. The Swedish Cancer Registry, Stockholm, was searched for records reporting malignancies in the study population (1958-84), and the expected number of malignancies was calculated on the basis of age- and sex-standardized incidence data. A malignancy was diagnosed in 36 patients with urticaria and the expected number of malignancies was 41. In 23 patients the malignancy appeared during the same year as the onset of urticaria or later. The expected number was 25.6. We conclude that chronic urticaria is not statistically associated with malignancy in general.
 ...
PMID:Chronic urticaria and cancer: an epidemiological study of 1155 patients. 209 76


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>